Orris

intrathecal dose of dexmed

Reading File
Finding Sources
Searching PubMed

intrathecal dexmedetomidine

Searching the Web

intrathecal dexmedetomidine dose not FDA approved 3 5 micrograms anesthesia

Intrathecal dexmedetomidine is off-label and should be administered only by an experienced anesthesiologist using an institutionally approved neuraxial protocol.
  • Typical adult adjuvant dose with spinal bupivacaine: 3-5 micrograms (mcg) preservative-free dexmedetomidine intrathecally.
  • Most commonly studied dose: 5 mcg.
  • Lower doses around 3 mcg can prolong sensory and motor block with less hemodynamic effect, as noted in Miller’s Anesthesia, 10e.
  • Doses 10 mcg or higher have been studied, but are more likely to prolong motor block and cause bradycardia/hypotension, so are not routine first-choice doses.
It is not FDA-approved for intrathecal administration. Avoid confusing mcg with mg. Use only preservative-free preparation and monitor for hypotension and bradycardia. Recent reviews in cesarean spinal anesthesia support improved block duration/analgesia but do not establish a universally approved standard dose, including a 2025 systematic review and 2024 meta-analysis.

What are the usual intrathecal dexmedetomidine adverse effects?

Reading File
Finding Sources
Searching PubMed

intrathecal dexmedetomidine adverse effects

Searching the Web

intrathecal dexmedetomidine systematic review adverse effects hypotension bradycardia neurotoxicity

Reading File
Usual adverse effects of intrathecal dexmedetomidine, particularly when used as a spinal anesthetic adjuvant, are:
  • Bradycardia: the main drug-related concern. It may need treatment with atropine if clinically significant.
  • Hypotension: risk is higher with larger doses, concurrent sympathectomy from spinal local anesthetic, hypovolemia, baseline low blood pressure, or other negative chronotropic drugs.
  • Sedation: usually mild, but may be more apparent at higher doses.
  • Prolonged motor block and delayed recovery of leg strength.
  • Prolonged sensory block, which can be desired but may delay mobilization and discharge.
  • Nausea/vomiting, usually secondary to hypotension rather than a distinctive direct effect.
  • Less commonly, shivering can occur, though dexmedetomidine may also reduce postoperative shivering in some settings.
Respiratory depression is not usually expected with low-dose intrathecal dexmedetomidine alone, unlike neuraxial opioids. The anesthesia text notes that alpha-2 agonists prolong subarachnoid anesthesia and analgesia, with associated bradycardia sometimes requiring atropine. Barash, Cullen, and Stoelting’s Clinical Anesthesia, 9e, p. 2843.
Important caveat: intrathecal administration remains off-label, and high-quality long-term human neurotoxicity data are limited. Therefore, use preservative-free drug, conservative dosing, and standard spinal-anesthesia monitoring. A recent systematic review and 2024 meta-analysis support analgesic/block-prolonging effects in cesarean spinal anesthesia, but do not create an approved universal safety standard.
This is a shared conversation. Sign in to Orris to start your own chat.